ストックスクリーナーアプリを入手
0.5367
0.36%
0.0019
前日終値:
$0.5348
開ける：
$0.54
24時間の取引高:
183.06K
Relative Volume:
0.44
時価総額：
$23.20M
収益：
-
当期純損益:
$-74.56M
株価収益率:
-0.293
EPS:
-1.8316
ネットキャッシュフロー:
$-60.27M
1週間 パフォーマンス:
-6.77%
1か月 パフォーマンス:
-9.56%
6か月 パフォーマンス:
+104.93%
1年 パフォーマンス:
-50.76%
1日の値動き範囲:
$0.5209
$0.56
1週間の範囲:
$0.49
$0.59
52週間の値動き範囲:
$0.2201
$1.2401
Rallybio Corp Stock (RLYB) Company Profile
RLYB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.5552 | 22.35M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.71 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.52 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.01 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.12 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.32 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-02-07 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-10 | 開始されました | Wedbush | Outperform |
| 2022-12-09 | 開始されました | JP Morgan | Overweight |
| 2022-02-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-08-23 | 開始されました | Cowen | Outperform |
| 2021-08-23 | 開始されました | Evercore ISI | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
すべてを表示
Rallybio Corp (RLYB) 最新ニュース
Will Rallybio Corporation stock beat EPS estimatesJuly 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
Risk adjusted return profile for Rallybio Corporation analyzedGap Up & Free Expert Approved Momentum Trade Ideas - newser.com
Using Ichimoku Cloud for Rallybio Corporation technicalsJuly 2025 Action & Precise Swing Trade Entry Alerts - newser.com
How Rallybio Corporation stock performs in rising dollar environmentWeekly Stock Recap & Safe Investment Capital Preservation Plans - newser.com
Analyzing Rallybio Corporation with risk reward ratio chartsJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - newser.com
Is Rallybio Corporation a candidate for recovery playJuly 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
Is Rallybio Corporation stock reversal real or fake2025 Valuation Update & Precise Buy Zone Identification - newser.com
Rallybio (NASDAQ:RLYB) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Rallybio Corporation stock outlook for YEAR2025 Trade Ideas & AI Powered Market Entry Strategies - newser.com
Best data tools to analyze Rallybio Corporation stockGap Up & Weekly High Conviction Ideas - newser.com
What Fibonacci levels say about Rallybio Corporation rebound2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
Is Rallybio Corporation stock attractive for growth ETFsWeekly Trade Analysis & Consistent Income Trade Recommendations - newser.com
Rallybio Corporation (NASDAQ:RLYB) Short Interest Update - Defense World
Will Rallybio Corporation stock benefit from automation2025 Price Momentum & Verified Swing Trading Watchlists - newser.com
Is it too late to sell Rallybio Corporation2025 Winners & Losers & Verified Technical Signals - newser.com
Analysts Set Rallybio Corporation (NASDAQ:RLYB) PT at $5.00 - Defense World
Using data tools to time your Rallybio Corporation exit2025 Year in Review & Weekly Top Gainers Alerts - newser.com
Can Rallybio Corporation stock deliver sustainable ROEQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
Top chart patterns to watch in Rallybio CorporationMarket Movement Recap & AI Enhanced Trading Signals - newser.com
Rallybio Corporation Stock Analysis and ForecastMarket Capitalization Trends & You’ll Regret Not Buying These Early - earlytimes.in
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study By Investing.com - Investing.com Nigeria
Rallybio Corp (RLYB) 財務データ
収益
当期純利益
現金流量
EPS
4.60%
0.11%
大文字化:
|
ボリューム (24 時間):